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Prolonged antibiotic prophylaxis use in
elective orthopaedic surgery – a cross-
sectional analysis
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Abstract
Purpose: Surgical antibiotic prophylaxis (SAP) prevents surgical site infections (SSI). In orthopaedic surgery, the use
of prolonged SAP (PSAP) has been reported in daily routine, despite guidelines advising against it. Therefore, we
asked: What is the proportion of PSAP use, defined as administration of SAP ≥24 h after elective orthopaedic
surgery? Are there patient- and surgery-related predictors of PSAP use?
Methods: This cross-sectional analysis investigated 1292 patients who underwent elective orthopaedic surgery
including total joint arthroplasties at one Swiss centre between 2015 and 2017. Patient comorbidities, surgical
characteristics and occurrence of SSI at 90 days in PSAP group were compared to the SAP group (< 24 h post-
operative).
Results: PSAP use was 12% (155 of 1292). Patient-related factors associated with PSAP compared to the SAP group
included older age (63 vs. 58y; p < 0.001), higher BMI (29 vs. 27 kg/m2; p < 0.001), ASA classification ≥3 (31% vs. 17%;
p < 0.001) and lung disease (17% vs. 9%; p = 0.002). Surgery-related factors associated with PSAP were use of
prosthetics (62% vs. 45%; p < 0.001), surgery of the knee (65% vs. 25%; p < 0.001), longer surgery duration (87 vs. 68
min; p < 0.001) and presence of drains (90% vs. 65%; p < 0.001). All four SSI occurred in the SAP group (0 vs. 4; p =
1.0). Surgeons administered PSAP with varying frequencies; proportions ranged from 0 to 33%.
Conclusion: PSAP use and SSI proportions were lower than reported in the literature. Several patient- and surgery-
related factors associated with PSAP use were identified and some were potentially modifiable. Also, experienced
surgeons seemed to implement differing approaches regarding the duration of SAP administration.
Keywords: Surgical antibiotic prophylaxis, Prolonged surgical antibiotic prophylaxis, Surgical site infection,
Orthopaedic surgery, Elective surgery, Prevention
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Introduction
Surgical site infections (SSI) can have devastating conse-
quences for patients. They are associated with inferior
patient outcomes as well as a high economic burden [1–
4]. SSI proportions are reported to be 1–5% in patients
undergoing major surgery [4–6]. Up to 55% of SSI are
estimated to be preventable with the use of evidence-
based strategies, including appropriate use of surgical
antibiotic prophylaxis (SAP) [7]. Although SAP is an
effective prevention measure [8], a safe use of SAP is
needed to prevent potential resistances and adverse
effects of antibiotics [9–11]. Heterogenous guidelines re-
flect the ongoing discussion about the optimal duration
of SAP. Several recommend discontinuing SAP within
24 h after operation [12–14]. Besides that, the 2017 U.S.
Centers for Disease Control and Prevention (CDC)
guideline even recommend against administration of
SAP after closure of the operation site in all clean or
clean-contaminated procedures [15]. Nevertheless, recom-
mendations on shortened SAP remain a matter of contro-
versy, especially in conditions with potentially higher risk
for SSI - including presence of a wound drain [16] - or
prosthetic procedures with high risk for devastating out-
comes if SSI occurs [17, 18]. A retrospective cohort study
found patients with total hip or knee arthroplasties (THA/
TKA) to be 4–5 times more likely to develop a peripros-
thetic joint infection (PJI) if they were not administered
extended oral SAP [19]. On the other hand, a recently
published meta- analysis of 51,627 total joint arthroplas-
ties (TJA) found no added benefit of prolonged antibiotic
prophylaxis (PSAP, defined as administration ≥24 h post-
operative) [20]. Therefore, the shortest effective and safe
duration of SAP in SSI prevention in orthopaedic surgery
remains a topic of debate.
Implementation and adherence to guidelines is report-
edly insufficient and non-adherence may even lead to
higher SSI proportions [6, 21, 22]. Furthermore, most
studies in the literature evaluate SSI and SAP in patients
undergoing either prosthetic surgery of the hip or knee
[8, 16, 18, 21, 23–26], knee arthroscopy [27, 28] or spinal
surgery [29–31]. To our knowledge, no study has re-
ported SAP use and SSI proportions in a broad popula-
tion undergoing elective orthopaedic surgery.
Methods
Aim
What is the proportion of PSAP use, defined as adminis-
tration of SAP ≥24 h after elective orthopaedic surgery?
Are there patient- and surgery-related predictors for
PSAP use?
Study design
This study is a cross-sectional analysis of elective ortho-
paedic operations between November 2015 and
September 2017 at one tertiary care centre in Bern,
Switzerland. The study protocol was approved by the
local ethics committee (PB_2016_00256). Written in-
formed consent was obtained from each patient.
Data collection
Patient characteristics and occurrence of SSI were pro-
spectively surveyed. Other data (surgical characteristics,
antibiotic prophylaxis) was retrospectively extracted
from the electronic patient file system (KISIM, Cistec
AG, Zurich, Switzerland). All relevant data was entered
into the secure web data storing system REDCap (Re-
search Electronic Data Capture, Version 8.5.19, Vander-
bilt University, Nashville, Tennessee, USA).
Participants
Patients for this study were initially recruited for the
randomized controlled trial (RCT) DECO- SSI (DECOl-
onisation and SSI), which investigated the impact of pre-
operative decolonization on the occurrence of SSI [32].
Inclusion criteria were a minimum age of 16 years and a
timeframe of at least 14 days before surgery. Each patient
was included in the study only once and for only one
operation. Exclusion criteria were: allergy to mupirocin
or chlorhexidine, the presence of a foreign nasal body,
pregnancy or planned intervention for a documented in-
fection. During the DECO-SSI study, all patients under-
went pre-operative screening for Staphylococcus aureus
by nose swab.
In this study, patients were grouped according to the
duration of administered SAP, irrespective of their S.
aureus carrier status. The SAP group received antibiotic
prophylaxis for a duration shorter than 24 h; including
those receiving no post-operative SAP at all and those
with SAP discontinued within 24 h after the operation.
The PSAP group consisted of patients who received SAP
for 24 h or longer (Fig. 1). The standard SAP at our
institution is Cefuroxime intravenous, one dose given 0-
60 min before incision with or without two doses admin-
istered 8 h and 16 h post-operative. Clindamycin is used
in case of allergy. Prescription of differing SAP or dur-
ation remained the responsibility of the treating surgeon,
depending on clinical assessment. Possible deviations are
analysed in this study.
Outcomes
Primary outcome was the number of patients receiving
PSAP, defined as administration of SAP ≥24 h post-
operative. The number of additional doses, dosing
regimen, route of administration and duration of post-
operative SAP were collected. To ensure that PSAP was
not prescribed for therapeutic reasons, all cases with
PSAP were reviewed by an internal medicine physician.
Patient files were screened for surgery site
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microbiological samples taken peri-operatively and for
reasons of antibiotic use other than prophylaxis; namely
for treatment of an infection at surgical site, hospital-
acquired or independent of surgery and hospital setting.
Two patients with findings consistent with an intra-
operative infection were excluded from this analysis.
Potential predictors for PSAP were the following: pa-
tient comorbidities and surgical characteristics including
type of anaesthesia, use of foreign material, operating
surgeon, drain use and post-operative transfusions. Sec-
ondary outcome was occurrence of SSI, which was pro-
spectively surveyed as part of the DECO-SSI trial by
telephone interview at 30 and 90 days [32]. SSI was de-
fined by CDC criteria [33].
Statistical analysis
Statistical analysis was performed by an independent
statistician from the clinical trials unit, University of
Bern, Switzerland. Continuous variables are shown as
mean with standard deviation. Comparisons were
made using Students T-test. Categorical data is shown
as number (%) and compared using Fisher’s exact
test. We calculated odds ratios (OR) with 95% confi-
dence intervals to quantify the association of patient
characteristics and surgery details with outcome using
logistic regression. In case of zero cells, we applied a
continuity correction of 0.5. We used logistic regres-
sion to investigate whether experienced surgeons ad-
ministered PSAP with the same frequencies included
the use of foreign material as covariate. Only sur-
geons who had carried out > 50 operations on pa-
tients in the study cohort were included in this
analysis. Based on surgeons’ proportion of operations
followed by PSAP, we selected a surgeon who had
neither the highest nor the lowest proportion as a
reference to derive OR. We compared the model fit
of the logistic regression with only surgeons with the
model fit when use of foreign material was included
as covariate using the likelihood ratio test. All other
analyses related to the entire study cohort. All ana-
lyses were carried out using Stata 16 (Stata Corp.,
College Station, Texas).
Results
A total of 1292 patients were included in this analysis
(Fig. 1). Patient average age was 58 years (±14) with
slightly more females (53%, 682 of 1292). Hip, knee and
spinal surgery accounted for most operations (424
(33%), 384 (30%) and 239 (18%) of 1292, respectively).
Prosthetic surgery accounted for 47% (613 of 1292).
Fig. 1 Patient flow chart
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PSAP use was 12% (155 of 1292). Duration of PSAP was
additional 3.3 (±1.5) doses ≥24 h after operation. This re-
sults in additional 27 (±15) hours of antibiotic prophylaxis
(Table 1, Fig. 2). In the SAP group, 11% (125 of 1137 pa-
tients) did not receive any post-operative SAP.
PSAP use was associated with older age (63 vs. 58
years; p < 0.001; OR 1.03/year), higher body mass index
(BMI) (29 vs. 27 kg/m2; p < 0.001; OR 1.06), American
Society of Anesthesiologists (ASA) classification ≥3 (31%
vs. 17%; p < 0.001; OR 1.6), known congestive or ische-
mic heart disease (10% vs 6%; p = 0.05; OR 1.84) and
known lung disease (17% vs. 9%; p = 0.002; OR 2.06)
(Table 2). Screening for malnutrition with the
nutritional-risk-score (NRS) was available for 23% of
Table 1 Antibiotic prophylaxis
Characteristics SAP (N = 1137) PSAP (N = 155) P-Value
Antibiotic agent 0.003
Cefuroxime 1000 (88%) 147 (95%)
Vancomycin 4 (0.35%) 3 (1.9%)
Clavulanic acid/ amoxicillin 0 (0.00%) 1 (0.65%)
Clindamycin 8 (0.70%) 4 (2.6%)
Number of consecutive post-operative intake doses < 24 h (number of patients)
0 125 (11%) 0
1 12 (1.1%) 0
2 999 (87.8%) 155 (100%)a
3 1 (0.1%) 0
Route of administration < 24 h 1.00
IV (intravenous) 1006 (88%) 154 (99%)
p.o. (peroral) 6 (0.53%) 1 (0.65%)
Number of consecutive intake doses ≥24 h (number of doses) n/a 3.3 (1.5)
Route of administration ≥24 h
IV (intravenous) n/a 152 (98%)
p.o. (peroral) n/a 3 (1.9%)
Antibiotic prophylaxis duration ≥24 h after surgery (in hours)b n/a 27 (15)
Presence of wound drain installed during operation 740 (65%) 139 (90%) < 0.001
Number of drains in surgical site 1.1 (0.27) 1.5 (0.53) < 0.001
Number of drains in surgical site < 0.001
1 686 (60%) 74 (48%)
2 53 (4.7%) 63 (41%)
3 1 (0.09%) 2 (1.3%)
Drain 1 - Duration of drain (in hours) 26 (11) 43 (14) < 0.001
Drain 2 - Duration of drain (in hours) 32 (16) 44 (10) < 0.001
Cumulative drain output (of all drains) (in ml) 131 (147) 224 (223) < 0.001
Post-operative transfusion of concentrated red blood cells 11 (0.97%) 2 (1.3%) 0.66
Other transfusion (platelet concentrate, fresh frozen plasma, albumin) 3 (0.26%) 0 (0.00%) 1.00
Record of NRS (Nutritional-Risk-score)c 247 (22%) 50 (32%) 0.004
Absolute NRS score 1.9 (0.85) 2.1 (1.0) 0.13
Surgical site infection 4 (0.35%) 0 (0.00%) 1.00
Footnote: Numbers are shown as mean (sd) or n (%)
aAll patients receiving PSAP, i. e. surgical antibiotic prophylaxis for more than 24 h, also received 2 doses of SAP in the first 24 h post-operative
bAntibiotic prophylaxis duration ≥24 h after surgery (in hours) = number of consecutive intake doses multiplied with time interval between doses in hours
cNRS score: screening tool for malnutrition. Internal nursing guidelines recommend collection of NRS score: if a stay ≥72 h is expected or one of the following
criteria is met: Patient ≥70 years old (NRS score at third day of hospitalization), BMI < 20 kg/m2 (NRS score at admission), patients with loss of appetite or apparent
malnutrition (NRS score at admission), patients undergoing major visceral operation (NRS score at third day of hospitalization), patients with known tumor disease
(NRS score at third day of hospitalization), patients undergoing chemotherapy (NRS score at admission), all patients at eighth day of hospitalization. If NRS score is
< 3 points weekly reevaluation is proceeded. NRS score ≥ 3 points needs intervention. NRS score ≥ 3 points is considered as light, = 4 points moderate and ≥ 5
points substantial energy and protein malnutrition
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patients with a mean absolute value of 1.9 (±0.88). Indi-
cations for screening are listed in Table 1. NRS was
significantly more frequently available for patients with
PSAP, whereby the score did not differ between PSAP
and SAP (2.1 ± 1.0 vs. 1.9 ± 0.85; p = 0.31).
PSAP patients underwent prosthetic surgery (62% vs.
45%; p < 0.001) and knee surgery (65% vs. 25%; p <
0.001) more often compared to SAP patients (Tables 2
and 3). Indeed, prosthetic surgery was more strongly as-
sociated with PSAP with an OR of 3.57 (95% CI: 1.92 to
6.64), as was knee surgery with an OR of 5.64 (95% CI:
3.95 to 8.06). In prosthetic hip surgery 2.8% (10 of 361)
were given PSAP whereas in prosthetic knee surgery
PSAP proportion was 35.7% (85 of 238) (Table 4). 101 of
155 PSAP had knee surgery, with 16 not receiving any
prosthetics. PSAP was also associated with a significantly
longer duration of operation (87 vs. 68 min; p < 0.001;
OR 1.01). The usage and number of drains at the surgi-
cal site (90% vs. 65%; p < 0.001 and 1.5 vs. 1.1; p < 0.001,
Fig. 2 Duration of post-operative surgical antibiotic prophylaxis in
PSAP group (N = 155) is shown in this plot
Table 2 Patient characteristics
Characteristics SAP (N = 1137) PSAP (N = 155) P-value OR (95% CI)
Age (years) 58 (14) 63 (12) < 0.001 1.03 (1.02 to 1.04)
Sex (female) 603 (53%) 79 (51%) 0.67 0.92 (0.66 to 1.29)
Active Smoking 206 (18%) 17 (11%) 0.031 0.56 (0.33 to 0.94)
Alcohol intake > 2 units/ daya 32 (2.8%) 3 (1.9%) 0.45 0.68 (0.21 to 2.25)
BMI (kg/m^2) 27 (4.8) 29 (5.6) < 0.001 1.06 (1.03 to 1.10)
bLung Disease 101 (8.9%) 27 (17%) 0.002 2.16 (1.36 to 3.44)
COPD 17 (1.5%) 5 (3.2%) 0.17 2.20 (0.80 to 6.04)
Asthma 36 (3.2%) 13 (8.4%) 0.005 2.80 (1.45 to 5.41)
Other severe lung disease 56 (4.9%) 17 (11%) 0.005 2.38 (1.34 to 4.21)
Congestive or ischemic heart disease 67 (5.9%) 16 (10%) 0.05 1.84 (1.04 to 3.26)
Liver disease 10 (0.88%) 0 (0.00%) 0.62 0.00 (0.00 to 2.81)
Renal insufficiency 9 (0.79%) 2 (1.3%) 0.63 1.64 (0.35 to 7.65)
Diabetes 72 (6.3%) 9 (5.8%) 1.00 0.91 (0.45 to 1.86)
Cerebrovascular disease (TIA or CVI) 35 (3.1%) 10 (6.5%) 0.06 2.17 (1.05 to 4.48)
ASA (calculated) < 0.001 1.65 (1.30 to 2.09)
1 406 (36%) 37 (24%)
2 537 (47%) 70 (45%)
3 192 (17%) 48 (31%)
4 1 (0.09%) 0 (0.00%)
Type of Surgery < 0.001
Spine 206 (18%) 33 (21%) 1.22 (0.81 to 1.85)
Hip 413 (36%) 11 (7.1%) 0.13 (0.07 to 0.25)
Upper extremity 95 (8.4%) 3 (1.9%) 0.22 (0.07 to 0.69)
Knee 283 (25%) 101 (65%) 5.64 (3.95 to 8.06)
Foot 140 (12%) 7 (4.5%) 0.34 (0.15 to 0.73)
Footnote: Numbers are shown as mean (sd) or n (%)
aAlcohol intake, 1 “unit” corresponds to approximately 2 cl of liquor, 1 dl of wine or 3 dl of regular beer; BMI, body mass index
bLung disease: multiple answers per patient were possible, e.g. presence of Asthma and a different severe lung disease in the same patient
COPD chronic obstructive pulmonary disease, TIA transient ischemic attack, CVI cerebrovascular insult, ASA American Society of Anesthesiologists
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respectively) as well as their cumulative output (224 vs.
131 ml; p < 0.001) were significantly higher in PSAP pa-
tients than in SAP (Table 1, Figs. 3 and 4). There was no
difference in terms of post-operative transfusion of
blood components.
Of all 30 orthopaedic surgeons involved, nine per-
formed over 50 operations as the main surgeon and were
evaluated concerning their frequency of PSAP use
(Table 3). The proportion of PSAP use ranged from 0 to
33%. Crude odds ratios for PSAP ranged from 0.14 (95%
CI 0.03 to 0.7; p = 0.017) to 5.0 (95% CI 2.0 to 12.4; p =
0.001) as compared to the reference surgeon. When ad-
justed for use of any foreign material (prosthesis, metal
or non-absorbable synthetic material), the range of odds
ratios was slightly larger and ranged from 0.13 (95% CI
0.03 to 0.66; p = 0.014) to 5.7 (95% CI 2.3 to 14.4; p <
0.001). The model when adjusted for foreign material fit-
ted better than the crude model (p < 0.001).
SSI were infrequent (4 of 1292, 0.3%), only occurring
in the SAP group (0 vs. 4; p = 1.000) (Table 1). All SSI
were early infections within 30 days post-operative. Two
patients with SSI underwent spine stabilization, one foot
(removal of foreign material) and one knee surgery (pri-
mary TKA). Microbiological samples showed one infec-
tion with Staphylococcus epidermidis (spine), no germ
(spine) and Staphylococcus aureus (foot). The patient
with TKA matched criteria for a superficial SSI, without
microbiological documentation.
Discussion
SSI present a high burden for the patient which lead to
increased mortality and morbidity, prolonged hospital
stay, reoperations and higher costs [1–4]. Prevention of
SSI is therefore essential. SAP is an effective measure to
prevent SSI [8, 12, 20, 34]. Nevertheless, recommenda-
tions regarding the optimal duration of SAP remain con-
troversial but several current guidelines are tending
towards shorter periods [13–15, 35]. One must now ad-
dress the problem of transferring the recently established
recommendations into common practice [6, 36]. In this
cross-sectional analysis we found the use of PSAP to be
12% at our centre and SSI proportions were 0.3% at 90
days. There were several patient- and surgery-related
factors associated with it, with some of them being po-
tentially modifiable. One strength of our study is that
the heterogenous cohort represents a realistic patient se-
lection found in daily surgical practice and includes a
variety of orthopaedic operations, no exclusion criteria
for comorbidities (apart from known infection before
surgery) and no restriction for advanced age.
Table 3 Surgical characteristics
Characteristics SAP (N = 1137) PSAP (N = 155) P-Value OR (95% CI)
Foreign material < 0.001
Prosthetic surgery 517 (45%) 96 (62%) 3.57 (1.92 to 6.64)
Metal or non-absorbable synthetic material 389 (34%) 47 (30%) 2.33 (1.21 to 4.48)
No foreign material 231 (20%) 12 (7.7%) Reference
Surgeon ≥50 operations < 0.001
A 183 (16%) 4 (2.6%) 0.19 (0.05 to 0.68)
B 125 (11%) 2 (1.3%) 0.14 (0.03 to 0.70)
C 179 (16%) 7 (4.5%) 0.33 (0.11 to 1.03)
D 87 (7.7%) 51 (33%) 4.98 (2.00 to 12.4)
E 126 (11%) 19 (12%) 1.28 (0.48 to 3.39)
F 123 (11%) 7 (4.5%) 0.48 (0.15 to 1.51)
G 49 (4.3%) 16 (10%) 2.78 (1.00 to 7.67)
H 59 (5.2%) 0 (0.0%) 0.00 (0.00 to 0.45)
I 51 (4.5%) 6 (3.9%) Reference
Duration of operation (minutes) 68 (41) 87 (45) < 0.001 1.01 (1.01 to 1.01)
Type of anesthesiaa
ITN (intubation anesthesia) 449 (39%) 51 (33%) 0.13 0.75 (0.53 to 1.07)
SPA (spinal anesthesia) 557 (49%) 90 (58%) 0.040 1.44 (1.03 to 2.02)
LMA (larynx mask anesthesia) 76 (6.7%) 9 (5.8%) 0.86 0.86 (0.42 to 1.75)
Regional anesthesia 64 (5.6%) 9 (5.8%) 0.85 1.03 (0.50 to 2.12)
Others 20 (1.8%) 0 (0.00%) 0.16 0.00 (0.00 to 1.39)
Numbers are shown as mean (sd) or n (%)
aType of anesthesia: multiple selection possible
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Prolonged surgical antibiotic prophylaxis use
Our PSAP proportion of 12% was lower than reported in
the literature. Although guidelines advise against PSAP,
several studies have identified its use in daily practice. In
one retrospective cohort study which included 34,133
patients undergoing major surgery, 59.3% of all patients
and 63.7% (9280 of 14,575) of those undergoing THA/
TKA were administered PSAP [6]. In THA/TKA the
median duration of SAP was 39 h. In another retrospect-
ive observational study, which evaluated 1019 patients
with TKA/THA, 21.7% of patients received PSAP [21].
One Swiss multicentre study of 2421 patients from all
Table 4 Type of surgery
Type of surgery SAP (N = 1137) PSAP (N = 155) p-value PSAP in %a
Spinal surgery (N = 239) N = 206 N = 33 0.80
Prosthetic surgery 0 (0.00%) 0 (0.00%)
Metal or synthetics 172 (83%) 27 (82%) 13.6%
No foreign material used 34 (17%) 6 (18%) 15.0%
Hip surgery (N = 424) N = 413 N = 11 1.00
Prosthetic surgery 351 (85%) 10 (91%) 2.8%
Metal or synthetics 55 (13%) 1 (9.1%) 1.8%
No foreign material used 7 (1.7%) 0 (0.00%) 0%
Upper extremity surgery (N = 98) N = 95 N = 3 0.52
Prosthetic surgery 13 (14%) 1 (33%) 7.1%
Metal or synthetics 40 (42%) 1 (33%) 2.4%
No foreign material used 42 (44%) 1 (33%) 2.3%
Knee surgery (N = 384) N = 283 N = 101 < 0.001
Prosthetic surgery 153 (54%) 85 (84%) 35.7%
Metal or synthetics 32 (11%) 14 (14%) 30.4%
No foreign material used 98 (35%) 2 (2.0%) 2.0%
Foot surgery (N = 147) N = 140 N = 7 0.70
Prosthetic surgery 0 (0.00%) 0 (0.00%)
Metal or synthetics 90 (64%) 4 (57%) 4.3%
No foreign material used 50 (36%) 3 (43%) 5.7%
aPSAP in %: percentage of PSAP patients per overall patients per parameter, e.g. prosthetic hip surgery 2.8% = 10 PSAP patients of overall 361 patients who
underwent prosthetic surgery of the hip
Fig. 3 The cumulative drain output in millilitres in SAP vs PSAP
patients is shown. If one patient had more than one drainage in
surgical site, the total output of all drains was calculated. Note that
the density function has no speaking unit, as it shows the
proportion of values within a certain interval relative to all values
Fig. 4 This figure shows duration of drainage after surgery in SAP vs
PSAP patients. Note that the density function has no speaking unit,
as it shows the proportion of values within a certain interval relative
to all values
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wards reported PSAP usage in 52.8% [22]. Two recent
studies in Ethiopia also investigated SAP use and SSI
rate. One retrospective study including 200 patients re-
ported 90% post-operative SAP use and SSI proportions
of 16% [37]. In contrast to our study, they included also
contaminated wounds. The cohort was younger than
ours (33 ± 15 vs 58 ± 14 years) and showed fewer known
comorbidities (86% with none). The second study re-
ported PSAP usage in 50.8% in patients undergoing dif-
ferent types of surgery, including orthopaedic, and an
SSI proportion of 11.1% prior to discharge [38]. These
two studies illustrate that a broad use of PSAP, even in
young and healthy patients, does not facilitate SSI
prevention.
Predictors of prolonged surgical antibiotic prophylaxis
To our knowledge, few studies have investigated reasons
for PSAP prescription. We found several factors associ-
ated with PSAP use, some of them being potentially
modifiable (e.g. presence and number of wound drains,
duration of surgery). In the literature, several of these
factors are also reported to be risk factors of SSI: older
age [23, 39], ASA score ≥ 3 [39–41], obesity [39, 41],
longer duration of operation [39–41], presence of wound
drain [41] and prosthetic surgery compared with
other procedures (including non- orthopaedic surgery)
[40]. Interestingly, a questionnaire for general sur-
geons on reasons for PSAP use revealed: drain use,
fever, leucocytosis, avoiding conflicts with patients,
and prescription for the surgeon’s own comfort and
feeling of confidence [42].
In our cohort, a large proportion of SAP patients
(65%, 740 of 1137) and an even higher percentage of
PSAP patients (90%, 139 of 155) had at least one drain.
In the literature, presence of drains and prolonged drain-
age were listed as potential risk factors for SSI [16, 43].
At our centre, drains were standardly removed on the
first post-operative day after clinical visit by the operat-
ing surgeon. Individual decisions for alternative removal
times were based on surgeons’ assessment. Several stud-
ies involving spinal surgery including drains found no
difference in SSI proportions between SAP for the dur-
ation for which the drain was in site versus SAP for 24 h
post-operative [29–31]. In addition, a meta-analysis and
a more recent RCT found no benefit of drains in hip
arthroplasty in connection with wound complications
[44, 45]. In a related matter, our hip team completely
abolished the routine use of drains during 2016. This
could partly explain the difference in PSAP use in pros-
thetics of the hip (2.8%) versus knee (35.7%), but as the
usage of drains was decreased gradually, no clear “before
& after” analysis was possible.
As drains were associated with PSAP use in our study
and do not seem to reduce surgical complications in the
literature, we suggest minimizing their usage (e.g. drain
reduction by means of hematoma reduction e.g. with use
of tranexamic acid [46]).
In our study, indications for PSAP were not avail-
able, therefore, no conclusion about the importance
or influence of one or several patient- or surgery- re-
lated factors on the decision-making process of the
operating surgeon is possible. Nevertheless, our data
indicates that surgeons have differing approaches,
with some prescribing PSAP more often than others.
Several studies investigating reasons for non-
adherence to guidelines reported: surgeon mistrust in
national guidelines due to perceived gaps in evidence,
continuing habits and administered protocols to date.
Other reasons included: institutional guidelines, fear
of legal pursuit in case of complications under short-
ened SAP and communication problems between sur-
geons, anaesthetists and nurses involved in the SAP
administration process [47, 48]. Therefore, preferences
of the operating surgeon might influence duration of
SAP.
The 0.3% SSI proportion at our centre was lower than
reported in literature for orthopaedic surgery. Data from
a 13-year multicentre SSI surveillance program in Swiss
hospitals reported proportions of 1.6 and 1.3% in elective
THA/TKA [5]. The following factors, also specified in
the literature to reduce SSI, might have contributed to
the low SSI proportions in our cohort: our voluntary
participation in a Surveillance Program [5, 13, 49–51],
having experienced and subspecialized orthopaedic sur-
geons, the inclusion of only elective procedures [52], as
well as the use of SAP [8, 12, 20, 34]. This study does
not allow a conclusion on the possible influence of post-
operative SAP on SSI numbers.
Some SSI might have been missed due to the study de-
sign which assessed SSI via telephone interview at 30-
and 90-days follow-up. A standardized clinical examin-
ation and a longer follow-up period (e.g. two years) to
evaluate occurrence of late onset infection, could have
enabled an optimal assessment.
Several current directives advise against any SAP in
clean surgery without implantation of foreign material
and a single pre-operative dose of SAP in other opera-
tions irrespective of prosthetic use [13–15, 35]. Address-
ing the shortening of SAP duration in orthopaedic
surgery and remaining uncertainties regarding the safety
for patients, Nagata et al. registered a multicentre, pro-
spective trial comparing 24 h SAP versus prolonged SAP
of 24 to 48 h in clean orthopaedic surgery
(UMIN000030929) [53]. In addition, a RCT investigating
peri-operative single- dose versus 24 h SAP in patients
undergoing elective TKA was registered in 2017
(Clinicaltrials.gov: NCT03283878). Results of both stud-
ies are still pending.
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Limitations
A key limitation is the cross-sectional design of the
study with retrospective survey of the use of SAP and
bias inherent to this study design apply. Indications for
PSAP use were therefore not available. However, the
survey of PSAP use in a prospective way would have
been comparable to an intervention and would have in-
fluenced results in our view. A further limitation is the
lack of data on pre-operative SAP administration as they
were not recorded in the electronic patient charts. Any-
way, the focus of the study laid on investigating PSAP as
pre-incisional SAP is well established.
Conclusion
In conclusion, we found room for improvement con-
cerning PSAP usage at our centre. Several potentially
modifiable factors were associated with PSAP, including
duration of operation or use of wound drains. Beside op-
timizing modifiable factors in order to reduce PSAP use,
surgeons require high levels of evidence of optimized
SAP resulting in low infection proportions with a high
safety profile in order to alter their prescribing practices.
In addition, a consistent continuation of programs for
SSI surveillance is needed to homogenize common
practice.
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